Skip to content
ClinCalc Pro
Menu
Alpha-2 Agonist — Analgesic Adjunct / Sedation

Clonidine

Brand names: Catapres, Duraclon (epidural)

Clonidine is a centrally acting alpha-2 adrenoceptor agonist used perioperatively as an anaesthetic adjunct and sedative, to attenuate sympathetic responses, reduce opioid requirements and treat postoperative shivering.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It stimulates central alpha-2 adrenoceptors in the brainstem, reducing sympathetic outflow and noradrenaline release, which lowers heart rate and blood pressure and produces sedation and analgesia.

Prescribing in practice

  • Abrupt withdrawal after sustained use can precipitate rebound hypertension and tachycardia, so taper rather than stop suddenly and avoid in patients with significant bradyarrhythmia.
  • Causes dose-dependent hypotension, bradycardia and sedation that can be additive with anaesthetic agents and other CNS depressants.
  • Use cautiously in cerebrovascular or ischaemic heart disease and in those with impaired renal function, who may need a reduced dose.

Monitoring

Monitor heart rate, blood pressure and conscious level closely during and after perioperative administration.

Counselling the patient

  • Expect drowsiness, a dry mouth and possible light-headedness when standing.
  • Do not stop the medicine abruptly if you have been taking it regularly.

Evidence & guidelines

Perioperative use is supported by anaesthetic guidance and trials showing reduced opioid requirement and attenuated haemodynamic stress responses.

Reference: Catapres SPC; PROSPECT Clonidine Review; Eisenach et al. (perineural clonidine); AAGBI; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.